29 Aprile 2019

European Approval Sought for Luspatercept for Anemias

April 26, 2019 – A marketing authorization application has been submitted to the European Medicines Agency for luspatercept for the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndrome (MDS)-associated anemia with ring sideroblasts who require red blood cell (RBC) transfusions and have not received or are ineligible to receive erythropoiesis-stimulating agents. The application for the agent is also for adult patients with beta-thalassemia … (leggi tutto)